Hematoloģija
Klīniskie rezultāti
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. (opens new window)
Avots: Lancet Haematol 2018;5(3):e117-e126.
Raksts indeksēts: PubMed 29396092
DOI: 10.1016/S2352-3026(18)30016-4
https://www.ncbi.nlm.nih.gov/pubmed/29396092 (opens new window)
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (opens new window)
Avots: Cancer 2013;119(1):107-14.
Raksts indeksēts: PubMed 22744794
DOI: 10.1002/cncr.27686
https://www.ncbi.nlm.nih.gov/pubmed/22744794 (opens new window)